ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Multifunctional Fe-Doped MOF-808 Nanocomposites for Chemo/Chemodynamic Synergistic Therapy.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Stimuli-Responsive Zirconium-Based Metal-Organic Frameworks for Targeted Cancer Drug Delivery.ACS applied materials & interfaces · 2026Review
- Metal-Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical Applications.Nano-micro letters · 2026Review
- Multifunctional Fe-Doped MOF-808 Nanocomposites for Chemo/Chemodynamic Synergistic Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Microenvironment-Activated Fe-MOF Nanoplatform Enables Controlled Doxorubicin Release and Ferroptosis-Associated Oxidative Damage in MCF-7 Breast Cancer Cells.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Theranostic nanomedicines combining targeted drug delivery and emerging therapeutic modalities with diagnosis are a rapidly evolving field in cancer therapy. In addition to conventional drug delivery, metal-organic frameworks (MOFs), consisting of metal ions/clusters and multitopic organic ligands, have been recently highlighted as ideal candidates for chemodynamic therapy (CDT) where active metal ions can be integrated at inorganic secondary building units or coordinated to linkers to act as CDT catalysts. Metal doping provides a potential approach to endow archetypal MOFs with enhanced CDT efficacy; herein, a novel PEGylated Fe-doped MOF-808 is reported, which is embedded with ultrasmall gold nanoparticles and manganese ions, can deliver carboplatin (CA) and achieve chemotherapeutic-chemodynamic (CT/CDT) synergistic therapy. 2D and 3D in vitro experiments demonstrate the synergistic therapeutic efficacy of CT and CDT, while the nanocomposite also shows magnetic resonance imaging potential. Therefore, this work provides a novel protocol to construct multi-metal doped MOFs as promising candidates in diagnostic and multimodal therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.